Drugs / NYX-2925
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 24 trials · 2 missed | ||||||
| Phase 2 | NCT04146896 | Nov 2019 → Feb 2022 | diabetic polyneuropathy | Aptinyx | Completed | Missed primary |
| Phase 2 | NCT04147858 | Nov 2019 → Jun 2022 | fibromyalgia | Aptinyx | Completed | Missed primary |
| Phase 2 | NCT03249103 | Aug 2017 → Apr 2019 | fibromyalgia | Aptinyx | Completed | No outcome recorded |
| Phase 2 | NCT03219320 | Jun 2017 → Nov 2018 | diabetic polyneuropathy | Aptinyx | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02834741 Comparator | Jul 2016 → Mar 2017 | — | Aptinyx | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NYX-2925 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03249103 ↗ |
| Action | Activate | “NYX-2925 is a small molecule that acts as an N-methyl-D-aspartate receptor (NMDAR) functional glycine-site partial agonist.” NCT02834741 ↗ |
| Modality | Small molecule | “NYX-2925 is a small molecule that acts as an N-methyl-D-aspartate receptor (NMDAR) functional glycine-site partial agonist.” NCT02834741 ↗ |
| Route | Oral | “study of oral NYX-2925 in healthy volunteers” NCT02834741 ↗ |